Here are some key insights from Wall Street on Tuesday: Piper Sandler has identified Microsoft as a top pick, stressing that the company’s stock is well-suited for the AI landscape. They noted, “We think Microsoft is probably the company with the most pure effort in AI adoption right now.” Meanwhile, Wells Fargo has upgraded FedEx from equal weight to overweight in anticipation of next week’s Investor Day, stating, “We expect to outline firm multi-year targets, and believe F27 could be a better year for Express’s earnings, creating solid upside room for consensus.”
Baird has lifted its rating on Palantir from neutral to better performance, calling the company one of the “clearest AI winners.” They noted that Palantir reported strong Q4 results, marking ten consecutive quarters of accelerating revenue growth driven by a boom in U.S. commercial activity.
JPMorgan has also upgraded SoFi from neutral to overweight, emphasizing that the company’s momentum is “undeniable.” They highlighted that while other fintechs are facing challenges, SoFi continues to gain new members and deposits at a record pace.
Morgan Stanley has raised its rating on Affirm from equal weight to overweight, stating they see attractive entry points. They expressed that the stock’s recent struggles are likely temporary. Additionally, Morgan Stanley reaffirmed its overweight ratings on Nvidia and Broadcom, noting that both stocks remain positive investments despite Nvidia presenting a more favorable price-to-earnings ratio.
Wells Fargo reiterated its bullish stance on Disney, saying it remains a top contender after its recent results. They believe the guidance for the second quarter is conservative and anticipate growth acceleration.
UBS has maintained a positive outlook on Amazon ahead of its earnings report later this week, raising its price target slightly from $310 to $311 due to increased estimates for AWS’s revenue and capital expenditures.
Bank of America has upgraded Popular from neutral to buy, projecting a 14% upside potential with a new price target of $156. They also upgraded Equity Lifestyle Properties to buy, citing strengths shown in the home manufacturing sector. Lastly, they’ve begun coverage on Actis Oncology, a biotech firm working on cancer treatments, giving it a buy rating and a price target of $34.
